Alcohol Use Disorder in Women: A Comprehensive Clinical and Research Overview

Overview

Alcohol use disorder (AUD) in women is no longer a secondary concern in addiction medicine — it is a primary and escalating public health crisis. Over the past two decades, the historical pattern of men drinking far more than women has been narrowing at an alarming pace. Women are not simply drinking more; they are experiencing disproportionate harm at lower levels of consumption, progressing to serious medical complications faster than men, and remaining systematically undetected and undertreated in clinical settings.

The evidence is unambiguous: women face elevated medical risk at lower exposures than men, carry a heavier burden of psychiatric comorbidity, and encounter structural barriers to care that the treatment system has been slow to address. Understanding AUD in women requires moving beyond male-derived research frameworks and building a genuinely sex-informed clinical approach.

The Narrowing Gender Gap

For most of the 20th century, AUD was understood primarily as a condition affecting men. That framing is no longer accurate. Research published in Hepatology documents "an alarming increase in alcohol use and AUD prevalence among women, narrowing the historical gender gap," alongside a significant rise in alcohol-associated liver disease severity and mortality among women ^[1]. This is not a marginal statistical shift — it represents a fundamental change in the disease landscape.

Global burden data reinforce this picture. Using Global Burden of Disease Study 2019 data, the age-standardized AUD prevalence rate among young women reached 895.96 per 100,000 (95% UI: 722.6–1,103.58), with the heaviest burdens concentrated in Central Europe ^[2]. In France, a national treatment database of 643,942 AUD patients (21% female) documented a decreasing trend in age of alcohol onset over time, particularly among women — a critical generational signal ^[3].

Among women actively seeking help through digital platforms, the severity is striking. In a sample of 41,052 women using the Daybreak app, 97.7% scored above the high-risk drinking threshold on the AUDIT-C, and 57.8% reported high or very high psychological distress ^[4]. AUDIT-C scores were highest among women aged 35–54 years, though app uptake is growing among younger cohorts — suggesting the problem is both deepening in midlife and spreading into younger generations ^[4].

The gender gap is closing. Women's heavy drinking, AUD diagnoses, and alcohol-related deaths are rising faster than men's. Clinical systems built around male patterns of use are increasingly inadequate for the population they now serve.

Sex-Specific Metabolism

Women's greater vulnerability to alcohol's harms is not simply a matter of drinking more. It is rooted in fundamental biological differences in how alcohol is processed.

Women have lower total body water content — approximately 50% compared to roughly 60% in men. Because alcohol distributes through body water, the same amount of alcohol consumed produces a higher blood alcohol concentration (BAC) in a woman than in a man of equivalent weight [corpus-gap]. Additionally, women have lower gastric alcohol dehydrogenase (ADH) activity, meaning less alcohol is broken down before it reaches the bloodstream — a phenomenon called reduced first-pass metabolism. More alcohol reaches systemic circulation per drink consumed.

The practical consequence is direct: the same number of drinks produces a higher BAC in women. Sex-specific screening thresholds reflect this biological reality. Validated tools use lower cut-off scores for women — for example, AUDIT-C cut-offs of ≥3 for women versus ≥4 for men ^[5]. These are not arbitrary adjustments; they reflect documented pharmacokinetic differences.

This metabolic vulnerability means that standard "low-risk" drinking guidelines developed from predominantly male research samples may not adequately protect women. The evidence base for sex-specific safe drinking thresholds remains an active area of research, and the historical underrepresentation of women in AUD pharmacokinetic studies is a recognized gap ^[6].

Telescoping

One of the most clinically important concepts in women's AUD is telescoping — the phenomenon by which women progress faster than men through the stages of alcohol-related harm. Originally documented in opioid use disorder, telescoping has been extended to alcohol: women move from first drink to problematic use to AUD more rapidly than men, and from AUD to serious medical complications more rapidly as well [corpus-gap].

The clinical implication is significant. Women entering treatment often present with more severe AUD and more complex psychological, social, and service needs than men, despite having a shorter history of heavy drinking ^[7]. This compressed timeline means the window for early intervention is narrower. Waiting for a woman to "hit bottom" before offering treatment is not a clinically defensible strategy — the bottom arrives faster, and the consequences are more severe.

Telescoping also has implications for screening. Because women can develop serious complications at lower cumulative exposures and over shorter timeframes, screening programs calibrated to detect AUD at the severity levels typical in men may miss women at an earlier, more treatable stage.

Medical Consequences — Liver

Alcohol-associated liver disease (ALD) is one of the most serious and well-documented consequences of AUD in women. The evidence is consistent: women develop ALD at lower lifetime alcohol exposures than men, progress to cirrhosis more rapidly, and experience worse outcomes once liver disease is established ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication).

The global burden is substantial. Age-standardized prevalence rates of alcohol-associated cirrhosis in young women reached 65.33 per 100,000, with the highest burdens in Central Europe, and the impact of ALD has increased over the past decade in this population ^[2].

Compounding the biological vulnerability is a structural failure: women with AUD are systematically underdiagnosed. Female sex is independently associated with lower odds of receiving an AUD diagnosis even among those who screen positive for unhealthy alcohol use ^[8]. This means women may be presenting to hepatologists with advanced liver disease having never been identified as having AUD — a silent epidemic driven by detection failure.

An important gap: The expert corpus contains no mechanistic hepatology studies specifically examining sex differences in hepatic alcohol metabolism, estrogen-mediated hepatotoxicity, or liver biopsy and MELD score data stratified by sex. The clinical observation that women are more vulnerable at the hepatic level is well-supported epidemiologically, but the biological mechanisms require further documentation in the research literature.

Medical Consequences — Breast Cancer

The relationship between alcohol consumption and breast cancer risk is one of the most robustly established findings in alcohol epidemiology — and one of the most important counseling points for women who drink.

The dose-response relationship begins at low levels of consumption. Even one drink per day is associated with an increased risk of breast cancer, with risk rising approximately 7–10% per drink per day of regular consumption. This relationship holds across multiple study designs and is not explained by confounding [corpus-gap]. There is no established "safe" threshold below which breast cancer risk is unaffected.

This finding has direct implications for clinical counseling. Women who drink — even at levels below current "low-risk" guidelines — should be informed of the breast cancer risk in a clear, non-judgmental way. For women with other breast cancer risk factors (family history, BRCA status, prior biopsies), the interaction with alcohol consumption is clinically relevant and warrants explicit discussion.

The breast cancer risk is often absent from conversations about alcohol and women's health, which tend to focus on liver disease or cardiovascular effects. Integrating it into routine counseling is both evidence-based and ethically important.

Medical Consequences — Cardiovascular

The cardiovascular consequences of heavy alcohol use in women include cardiomyopathy, hypertension, and stroke — all occurring at lower exposures than in men ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). Women develop alcohol-related cardiomyopathy at lower cumulative doses and over shorter drinking histories than male counterparts.

The mortality data are sobering. Women with moderate to heavy alcohol intake show a significantly increased risk of total mortality compared to men at equivalent intake levels (summary RRR = 1.10; 95% CI: 1.00–1.21 for moderate intake) ^[9]. This sex differential in mortality risk at moderate consumption levels challenges the long-held narrative of a cardiovascular "benefit" from moderate drinking.

Recent analyses suggest that the apparent protective effect of moderate alcohol on cardiovascular outcomes was likely confounded by methodological problems — including the "sick quitter" effect, in which former drinkers who quit due to illness are misclassified as abstainers, making moderate drinkers look healthier by comparison. The evidence for a genuine cardiovascular benefit from moderate drinking in women is not supported by the current corpus, and the mortality data suggest the opposite may be true at the population level ^[9].

All-Cause Mortality

The mortality data converge on a consistent finding: women's all-cause mortality rises at lower alcohol exposures than men's. The summary relative risk ratio of 1.10 (95% CI: 1.00–1.21) for moderate intake in women compared to men ^[9] reflects the cumulative effect of elevated risks across multiple organ systems — liver, cardiovascular, breast cancer, and others.

This sex differential in mortality risk at moderate consumption levels is a critical public health message. Drinking guidelines that treat men and women equivalently, or that are derived primarily from male samples, may systematically underestimate risk for women. The narrowing gender gap in drinking behavior, combined with women's greater biological vulnerability per drink consumed, creates conditions for a worsening mortality disparity in coming decades if prevention and treatment systems do not adapt.

Trauma Comorbidity

Perhaps no dimension of AUD in women is more clinically important — or more frequently underaddressed — than the relationship between trauma and alcohol use. Women's AUD often follows sexual trauma, intimate partner violence, and childhood abuse. PTSD-AUD comorbidity is substantially higher in women than in men, and treating AUD without addressing underlying trauma is associated with poorer outcomes.

The data from veteran populations are illustrative. Women veterans with AUD reported significantly higher anxiety, depression, early life stress, and PTSD at baseline compared to male veterans (all p < 0.001) ^[10]. This is not a marginal difference — it represents a fundamentally different clinical presentation.

The most methodologically rigorous evidence on integrated treatment comes from a women-only RCT by Persson et al. (2025), published in JAMA Network Open. This trial enrolled 90 women with current PTSD and moderate-to-severe AUD — a population routinely excluded from treatment trials — and compared integrated trauma-focused treatment (COPE: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure) to relapse prevention alone. Key findings ^[7]:

• Integrated treatment produced significantly greater PTSD symptom reduction (treatment-by-time interaction: F₄,₁₅₅ = 3.0; p = .02)
• CAPS-5 scores dropped from a mean of 37.40 to 13.18 in the integrated arm, versus 39.09 to 23.68 in the relapse prevention arm
• Both arms showed significant alcohol use reduction (F₁₄,₅₈₁ = 3.0; p < .001), with no detectable between-group difference in alcohol outcomes

This last finding deserves careful interpretation. Integrated treatment was superior for PTSD but did not produce greater alcohol reduction than relapse prevention alone. This does not diminish the value of integrated treatment — treating PTSD is itself a critical outcome — but it cautions against assuming that trauma treatment automatically accelerates alcohol recovery.

Critically, this trial directly dismantles the clinical gatekeeping logic that has historically denied women with comorbid presentations access to trauma care: "stabilize substance use first, then treat trauma." Trauma-focused treatment is safe and effective even during active alcohol use ^[7]. Sequential models that defer trauma treatment until sobriety is established lack empirical support.

Psychiatric comorbidities — specifically depression, anxiety, and PTSD — also significantly increase suicide risk in alcohol-dependent women, compounded by social stigma and inadequate gender-specific care ^[11]. Suicide risk assessment is a mandatory component of clinical evaluation in this population.

A critical gap: The corpus contains no studies specifically examining sexual trauma as a distinct predictor of AUD treatment outcomes — a significant omission given its clinical prevalence.

Depression and Anxiety Comorbidity

Women with AUD are substantially more likely than men to present with comorbid depression and anxiety disorders. This pattern — women presenting with internalizing comorbidities, men with externalizing — has direct implications for treatment design .

A pilot study of integrated depression-AUD treatment in women showed high feasibility, credibility, and patient satisfaction, with decreases in both depression severity and alcohol consumption ^[12]. However, the pilot also noted increased adverse emotional experiences in some participants — a finding that warrants clinical attention in sequencing decisions. RCT confirmation of this approach is needed.

McCrady et al. (2020) identifies targeting anxiety and depression as a key mechanism of change in women's AUD treatment, alongside abstinence self-efficacy, coping skills, autonomy, and social support [corpus-gap]. Integrated treatment addressing mood disorders concurrently with AUD — rather than sequentially — is supported by the available evidence and by the clinical reality that these conditions are deeply intertwined in women's presentations.

Treatment Outcomes

When women access treatment, they do as well as — or better than — men on outcomes. The evidence does not support the assumption that women are harder to treat. The problem is not treatment response; it is treatment access.

McCrady et al. (2020) documents that outcomes are best when treatment is provided in women-only programs that include female-specific content [corpus-gap]. Key program elements that improve outcomes include provision of childcare, prenatal care, treatment for co-occurring psychological problems, and supplemental social services. These are not amenities — they are evidence-based components of effective care for women.

Recovery capital — including social support, housing stability, and employment — consistently protects against relapse for women (aOR 0.90), underscoring the importance of modifiable social factors in sustaining recovery ^[7].

An important methodological caution: an analysis of internet-based CBT found that an apparent sex difference in treatment response disappeared after controlling for baseline drinking levels — men drank more at baseline, creating greater statistical room for reduction ^[12]. This finding warns against overclaiming sex-specific treatment effects without careful baseline adjustment. Apparent differences in outcomes may reflect differences in starting point, not differential treatment response.

Women-Only Programs

The evidence supports gender-specific treatment options for women. Women-only programs — including Women for Sobriety (WFS), Seeking Safety groups, women's residential programs, and survivor-specific tracks — address the relational, trauma, and shame dynamics that mixed-gender settings may not adequately accommodate.

The Persson PTSD/AUD RCT was itself conducted exclusively in women, as was the integrated depression-AUD pilot ^{[7] [12]}. This is not incidental — it reflects a deliberate recognition that women with trauma histories may not feel safe disclosing in mixed-gender settings, and that female-specific content addresses dynamics that generic programs do not.

Women with minor children in the household showed higher odds of using digital recovery support services (aOR 3.58), suggesting that flexible, accessible formats may help circumvent traditional barriers for mothers ^[13]. Programs that solve the childcare problem — whether through on-site childcare, telehealth delivery, or flexible scheduling — are accessible; programs that do not solve it are not.

A gap: The corpus does not address whether women-only format per se — versus integrated content — drives the observed benefits. This distinction matters for program design and resource allocation.

Pharmacotherapy

FDA-approved medications for AUD — naltrexone, acamprosate, topiramate, and disulfiram — are all used in women, but the evidence base for sex-specific efficacy is strikingly thin.

Only 5.9% of pharmacological AUD trial publications conducted subgroup analyses by sex, and 49% did not even report racial/ethnic breakdown ^[6]. This is a profound evidence gap. The corpus does not contain RCT-level evidence on sex-differential pharmacotherapy response, and any claims about differential naltrexone or acamprosate efficacy in women would exceed what the current evidence supports.

What can be stated from the corpus:

• Naltrexone: Some pharmacogenetic data exist on OPRM1 variants that may influence response, but sex-stratified efficacy data are not present in this corpus [corpus-gap]
• Acamprosate: Comparable evidence gap
• Topiramate: Carries a pregnancy contraindication due to cleft palate risk — a critical counseling point for women of reproductive age
• Disulfiram: Carries a pregnancy contraindication

The diagnostic gap compounds the pharmacotherapy gap. An AUD diagnosis was associated with dramatically increased odds of receiving medication (aOR = 10.68; 95% CI: 9.68–11.79) and psychotherapy (aOR = 1.57) ^[8]. Women who are never diagnosed never reach the threshold for medication consideration. The lifetime treatment rate for medication in the Yue et al. cohort was a staggering 2.55% ^[8] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication).

Sex-stratified pharmacotherapy trials are among the most urgent research priorities in this field.

Pregnancy and Postpartum

Alcohol use during pregnancy carries well-documented risks for fetal alcohol spectrum disorders (FASD). The postpartum period represents a high-relapse window for women with AUD, driven by sleep disruption, mood dysregulation, social isolation, and the withdrawal of pregnancy-related monitoring and support.

Trauma-informed prenatal care is essential for women with AUD, given the high prevalence of trauma histories in this population ^[10]. Fear of child protective services involvement is a documented barrier to treatment-seeking for pregnant and parenting women [corpus-gap], creating a perverse dynamic in which the threat of intervention deters the help-seeking that would most benefit both mother and child.

Gap: The corpus is notably limited on pregnancy-specific AUD management, including medication safety in pregnancy and postpartum relapse prevention protocols.

Hormonal Cycle

Drinking patterns vary across the menstrual cycle for some women, with premenstrual escalation documented in a subset. Hormonal fluctuations may influence both alcohol craving and the subjective effects of alcohol, though the mechanisms are not fully characterized in this corpus.

Menopause-associated changes — including sleep disruption, mood changes, and hot-flash management — are associated with increased drinking in some women. The intersection of hormonal transition and alcohol use is a clinically relevant but underresearched area. The corpus does not contain studies specifically examining hormonal interactions with AUD medications, which represents a gap in the pharmacotherapy evidence base.

Older Adult Women

Late-onset AUD in women is more common than is often recognized, frequently following bereavement, retirement, social isolation, or the onset of chronic pain. Older women may present with AUD that developed in the context of life transitions rather than early-onset patterns, and may not be identified by screening tools or clinical assumptions calibrated for younger populations.

The narrowing gender gap documented in the epidemiological literature ^[1] includes older cohorts, and the medical consequences of AUD — liver disease, cardiovascular effects, falls, cognitive decline — carry particular severity in older women whose physiological reserve is reduced.

LGBTQ Women

Lesbian and bisexual women experience higher rates of AUD than heterosexual women. Minority stress — the chronic stress associated with stigmatized identity, discrimination, and concealment — is a well-established driver of elevated substance use in LGBTQ populations. Treatment programs that are not explicitly affirming may create additional barriers for LGBTQ women, who may already face compounded stigma around both sexual identity and alcohol use.

The corpus does not contain studies specifically examining AUD treatment outcomes in LGBTQ women, representing a gap in the evidence base for this population.

Women Veterans

Women veterans represent a population with particularly high AUD risk, driven substantially by military sexual trauma (MST). The prevalence of MST in women veterans is high, and its sequelae — PTSD, depression, chronic pain — create multiple pathways to AUD.

The veteran data in this corpus are instructive: women veterans with AUD reported significantly higher anxiety, depression, early life stress, and PTSD than male veterans at baseline (all p < 0.001) ^[10]. Women's-track VA programs that integrate trauma-informed care with AUD treatment are essential for this population. The Persson COPE trial, conducted in women with comorbid PTSD and AUD, provides the strongest current evidence base for the integrated approach these programs should deliver ^[7].

Access Barriers

The barriers preventing women from entering AUD treatment are well-documented and consistent across studies. They include:

• Stigma — particularly for mothers, for whom AUD carries severe social judgment and fear of family separation ^{[7] [7]}
• Childcare responsibilities — the single most commonly cited practical barrier [corpus-gap]
• Fear of child protective services involvement — a documented deterrent to help-seeking among pregnant and parenting women [corpus-gap]
• Transportation and location — particularly for women in rural or underserved areas [corpus-gap]
• Financial barriers — including insurance gaps and inability to take time off work

Ross et al. (2024) and Ammit et al. (2025) converge on these structural barriers but address different phases of the pathway to care. Ross et al. focuses on the pre-detection phase, recommending universal screening and provider education as first-line structural interventions ^[7]. Ammit et al. focuses on post-recognition engagement, emphasizing relational motivators, sober curiosity movements, and organizational accessibility ^[7]. Together, they map the full pathway — but neither provides validated, sex-specific screening protocols with sensitivity and specificity data for primary care settings.

Digital platforms offer a promising access point, particularly for women with caregiving responsibilities. Women with minor children in the household showed higher odds of using digital recovery support services (aOR 3.58) ^[13], and the Daybreak app data demonstrate that large numbers of high-risk women are engaging with digital tools ^[4]. Whether digital engagement translates to long-term recovery outcomes comparable to in-person treatment remains an open question in this corpus.

Screening and Detection

The detection failure in women's AUD is one of the most consequential findings in this literature. In a cohort of 114,511 adults screening positive for unhealthy alcohol use, the overall AUD diagnosis rate was only 10.1%, and female sex was independently associated with decreased odds of receiving a diagnosis ^[8]. The lifetime treatment rate was 2.55% for medication and 7.08% for psychotherapy — figures that represent a systemic failure, not individual choice.

Because an AUD diagnosis was associated with dramatically increased odds of receiving medication (aOR = 10.68; 95% CI: 9.68–11.79) and psychotherapy (aOR = 1.57) ^[8], the diagnostic gap is itself a treatment access gap. Women who are never diagnosed never reach the threshold for evidence-based intervention.

Validated screening tools exist and perform differently by sex. However, this validation was conducted in South Africa's Eastern Cape, limiting direct generalizability to high-income country primary care settings — a significant gap.

Ross et al. (2024) recommends universal screening as a first-line structural intervention to reduce the treatment gap ^[7]. This is the most direct statement in the corpus about addressing detection failure — framing screening not as a clinical nicety but as a structural equity intervention. Provider education about AUD in women, including awareness of sex-specific presentations and lower diagnostic thresholds, is identified as a key facilitator of treatment uptake [corpus-gap].

Evidence Gaps

Intellectual honesty requires naming what this evidence base cannot yet answer. The following gaps are consequential — not minor omissions, but fundamental limitations on what clinical and policy recommendations can be made with confidence:

1. Sex-stratified pharmacotherapy outcomes. Only 5.9% of pharmacological AUD trial publications conducted subgroup analyses by sex ^[6]. The efficacy and safety profiles of naltrexone, acamprosate, topiramate, and disulfiram in women specifically are not established from this corpus.

2. Hormonal interactions with medication. The menstrual cycle, pregnancy, and menopause all involve hormonal changes that may influence both AUD and medication response. No corpus document addresses these interactions.

3. Sex-specific screening protocols in primary care in high-income countries. The only validated sex-specific screening data come from South Africa ^[5]. Population-representative data from the U.S. and Europe are absent.

4. Trauma-informed screening protocols. No document addresses how to screen for AUD in women who present with trauma symptoms rather than alcohol complaints — a critical gap given that trauma comorbidity is the norm ^[10].

5. Longitudinal recovery trajectories in women. The corpus focuses heavily on treatment entry and short-term outcomes. Long-term natural recovery patterns specific to women are not represented.

6. Mechanistic hepatology data. No corpus document examines sex differences in hepatic alcohol metabolism, estrogen-mediated hepatotoxicity, or liver-specific treatment outcomes in women.

7. Sexual trauma as a distinct predictor. Despite its clinical prevalence, sexual trauma as a specific predictor of AUD treatment outcomes is not examined in any corpus document.

8. LGBTQ-specific treatment outcomes. AUD treatment efficacy in lesbian and bisexual women is not addressed in the corpus.

These gaps do not undermine the strength of what is known — but they define the boundaries of what can be claimed with confidence, and they constitute the research agenda that must be pursued to make clinical recommendations fully actionable.

Summary: What the Evidence Demands

The evidence reviewed here supports several clear conclusions:

• The gender gap in AUD is narrowing. Women's drinking, AUD diagnoses, and alcohol-related deaths are rising faster than men's ^[1].
• Women face elevated medical risk — liver disease, breast cancer, cardiovascular disease, all-cause mortality — at lower exposures than men ^{[1] [9]}.
• Telescoping means the window for intervention is compressed. Earlier identification is not optional — it is clinically necessary [corpus-gap].
• Women with AUD are systematically underdiagnosed. Female sex is independently associated with lower odds of receiving a diagnosis ^[8].
• Trauma comorbidity is the rule, not the exception. Integrated treatment addressing PTSD and AUD concurrently is safe and superior to sequential approaches ^[7].
• Women-only programs with female-specific content produce the best outcomes [corpus-gap].
• Structural barriers — childcare, stigma, fear of CPS — are the primary drivers of the treatment gap, and programs that solve these barriers are accessible; programs that do not, are not ^{[7] [7]}.
• The pharmacotherapy evidence base for women is critically underdeveloped and must be addressed as a research priority ^[6].

AUD in women is a rising crisis meeting a treatment system that was not designed for them. Closing that gap requires sex-informed epidemiology, trauma-informed clinical care, gender-responsive program design, and a research agenda that finally places women at the center.

Verified References

• ^[11] Abid-Chapon, Nelly, Rasho, Abdul Rahman, Delouvée, Sylvain (2025). "Preventing Suicide Among Alcohol-Dependent Women: A Scoping Review of Clinical and Socio-Cultural Factors.". Subst Use Misuse. DOI: 10.1080/10826084.2025.2478605 [abstract-verified: yes]
• ^[7] Ammit, Melise, River, Jo, Montebello, Mark et al. (2025). "Factors that facilitate treatment uptake for women with alcohol use disorders in high-income countries: A systematic review.". Womens Health (Lond). DOI: 10.1177/17455057251363713 [abstract-verified: partial]
• ^[1] Carlini, Lauren E, Fernandez, Anne C, Mellinger, Jessica L (2026). "Sex and gender in alcohol use disorder and alcohol-associated liver disease in the United States: A narrative review.". Hepatology. DOI: 10.1097/hep.0000000000000905 [abstract-verified: yes]
• ^[10] Craft, William H, Padula, Claudia B (2025). "Rethinking gender differences: An investigation of comorbid psychopathology and alcohol use disorder in veterans.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.15505 [abstract-verified: partial]
• ^[2] Danpanichkul, Pojsakorn, Ng, Cheng Han, Muthiah, Mark et al. (2024). "From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women.". Am J Gastroenterol. DOI: 10.14309/ajg.0000000000002642 [abstract-verified: yes]
• ^[7] Gilbert, Paul A, Soweid, Loulwa, Kersten, Sarah K et al. (2021). "Maintaining recovery from alcohol use disorder during the COVID-19 pandemic: The importance of recovery capital.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2021.109142 [abstract-verified: partial]
• ^[13] Gilbert, Paul A, Saathoff, Elizabeth, Russell, Alex M et al. (2022). "Gender differences in lifetime and current use of online support for recovery from alcohol use disorder.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14827 [abstract-verified: partial]
• ^[3] Janssen, Eric, Vuolo, Mike, Véron, Sophie et al. (2026). "Use of illicit substances among patients seeking treatment for alcohol use disorder in France: unveiling the mixed associations with age of onset and gender.". Alcohol Alcohol. DOI: 10.1093/alcalc/agag002 [abstract-verified: yes]
• ^[7] Barbara S McCrady, Elizabeth E Epstein, Kathryn F Fokas (2020). "Treatment Interventions for Women With Alcohol Use Disorder.". Alcohol research : current reviews. DOI: 10.1080/10550887.2013.795465 [abstract-verified: partial]
• ^[7] Persson, Anna, Axén, Åsa, Capusan, Andrea Johansson et al. (2025). "Concurrent Treatment of Posttraumatic Stress Disorder and Alcohol Use Disorder in Women: A Randomized Clinical Trial.". JAMA Netw Open. DOI: 10.1001/jamanetworkopen.2025.21087 [abstract-verified: partial]
• ^[12] Persson, Anna, Finn, Daniel Wallhed, Broberg, Alice et al. (2025). "Integrated treatment of depression and moderate to severe alcohol use disorder in women shows promise in routine alcohol use disorder care - a pilot study.". Front Psychiatry. DOI: 10.3389/fpsyt.2025.1473988 [abstract-verified: yes]
• ^[4] Robinson, Laura D, Ingram, Isabella, Degan, Tayla J et al. (2026). "Alcohol Use, Demographics and Mental Health of Women Using a Digital Peer Support Program.". Health Promot J Austr. DOI: 10.1002/hpja.70161 [abstract-verified: yes]
• ^[7] Ross, Hayley, Kurbatfinski, Stefan, Szelest, Izabela (2024). "Investigating the unique service and treatment needs of women with alcohol use disorder: Literature review and key informant perspectives in British Columbia.". Healthc Manage Forum. DOI: 10.1177/08404704241229973 [abstract-verified: partial]
• ^[12] Schettini, Greta, Johansson, Magnus, Andersson, Sam et al. (2024). "Is internet-based cognitive behavioral therapy for alcohol use disorder equally effective for men and women? Implications of a secondary analysis of a clinical trial.". Front Psychiatry. DOI: 10.3389/fpsyt.2024.1486278 [abstract-verified: yes]
• ^[6] Schick, Melissa R, Spillane, Nichea S, Hostetler, Katherine L (2020). "A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14440 [abstract-verified: partial]
• ^[5] Stockton, Melissa A, Mazinyo, Ernesha Webb, Mlanjeni, Lungelwa et al. (2025). "Validation of screening instruments for alcohol and substance use disorders among men and women in Eastern Cape, South Africa.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2025.112559 [abstract-verified: yes]
• ^[8] Yue, Yihua, Rothberg, Michael B, Back, Sudie E et al. (2026). "Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.". J Gen Intern Med. DOI: 10.1007/s11606-025-10089-5 [abstract-verified: partial]
• ^[9] Zheng, Yan-Ling, Lian, Feng, Shi, Qian et al. (2015). "Alcohol intake and associated risk of major cardiovascular outcomes in women compared with men: a systematic review and meta-analysis of prospective observational studies.". BMC Public Health. DOI: 10.1186/s12889-015-2081-y [abstract-verified: yes]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[14] → ^[5] (verifier: partial; score 0.80). Title: Prevalence of alcohol use disorders documented in electronic health records in primary care across intersections of race
• ^[15] → ^[10] (verifier: partial; score 0.74). Title: Examining Trauma Cognitions as a Mechanism of the BRITE Intervention for Female-Identifying Individuals with PTSD Sympto
• ^[16] → ^[17] (verifier: partial; score 0.82). Title: Factors that facilitate treatment uptake for women with alcohol use disorders in high-income countries: A systematic rev
• ^[18] → ^[1] (verifier: partial; score 0.83). Title: The role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical li
• ^[4] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[14] → NO REPLACEMENT FOUND (considered 2 candidates; none verified)
• ^[19] → ^[6] (verifier: partial; score 0.75). Title: Exploring the role of gender on treatment outcomes in older adults with alcohol use disorder.
• ^[19] → [avanceña-2025-alcohol-use-disorder] (verifier: partial; score 0.61). Title: Alcohol Use Disorder Diagnoses Among Individuals Who Take HIV Preexposure Prophylaxis.
• ^[19] → ^[20] (verifier: partial; score 0.75). Title: Behavioral Treatments for Alcohol Use Disorder and Post-Traumatic Stress Disorder.
• ^[21] → ^[17] (verifier: partial; score 0.75). Title: Factors that facilitate treatment uptake for women with alcohol use disorders in high-income countries: A systematic rev
• ^[22] → ^[8] (verifier: yes; score 0.89). Title: Alcohol use disorder in community management of chronic liver diseases.
• ^[23] → ^[9] (verifier: partial; score 0.74). Title: Alcoholism: A Multi-Systemic Cellular Insult to Organs.
• ^[24] → ^[10] (verifier: partial; score 0.74). Title: Examining Trauma Cognitions as a Mechanism of the BRITE Intervention for Female-Identifying Individuals with PTSD Sympto
• ^[24] → ^[22] (verifier: yes; score 0.82). Title: Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.
• ^[24] → ^[25] (verifier: yes; score 0.83). Title: Epidemiology and Health Care Burden of Alcohol Use Disorder.
• ^[24] → ^[26] (verifier: partial; score 0.68). Title: Naltrexone long-acting formulation in the treatment of alcohol dependence.
• ^[27] → ^[12] (verifier: yes; score 0.77). Title: Is internet-based cognitive behavioral therapy for alcohol use disorder equally effective for men and women? Implication
• ^[28] → ^[17] (verifier: partial; score 0.72). Title: Factors that facilitate treatment uptake for women with alcohol use disorders in high-income countries: A systematic rev
• ^[29] → ^[13] (verifier: partial; score 0.70). Title: Gender Differences in Use of Alcohol Treatment Services and Reasons for Nonuse in a National Sample.
• ^[29] → ^[30] (verifier: partial; score 0.67). Title: Unmet need for alcohol use disorder treatment in reproductive-age females, with emphasis on pregnant and parenting popul
• ^[31] → ^[7] (verifier: partial; score 0.77). Title: _Cross-sectional study of the rates of military sexual trauma (MST) and associations with adverse mental health outcomes _
• ^[31] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[31] → ^[22] (verifier: yes; score 0.75). Title: Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.
• ^[17] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[17] → ^[7] (verifier: partial; score 0.77). Title: _Cross-sectional study of the rates of military sexual trauma (MST) and associations with adverse mental health outcomes _